2019
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI, Leighl NB, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N, Tashbar J, Yankelevitz D, Altorki N. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. Journal Of Clinical Oncology 2019, 38: 753-766. PMID: 31829901, DOI: 10.1200/jco.19.02748.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Non-Small-Cell LungDecision MakingEvidence-Based MedicineHumansLung NeoplasmsNeoplasm StagingObservational Studies as TopicRandomized Controlled Trials as TopicRetrospective StudiesConceptsCurative-intent therapyLung cancerStage IFluorodeoxyglucose positron emission tomography/Evidence-based guideline recommendationsNew primary lung cancerRetrospective comparative observational studySurveillance strategiesSmall cell lung cancerBrain magnetic resonance imagingLiterature searchPositron emission tomography/Lung cancer surveillanceCurative-intent treatmentPrimary lung cancerRecurrence-free survivalCell lung cancerDetection of recurrenceComparative observational studyEmission tomography/Optimal imaging modalityEvidence-based recommendationsOutcomes of interestQuality of lifeMagnetic resonance imaging
2013
Thoracoscopy A Real-Life Perspective
Detterbeck FC. Thoracoscopy A Real-Life Perspective. Clinics In Chest Medicine 2013, 34: 93-98. PMID: 23411060, DOI: 10.1016/j.ccm.2012.12.002.Peer-Reviewed Original ResearchHumansPleural DiseasesRandomized Controlled Trials as TopicThoracic Surgery, Video-AssistedThoracoscopy
2012
Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review
Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review. JAMA 2012, 307: 2418-2429. PMID: 22610500, PMCID: PMC3709596, DOI: 10.1001/jama.2012.5521.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesHumansLung NeoplasmsRadiation DosageRandomized Controlled Trials as TopicRiskRisk Reduction BehaviorTomography, X-Ray ComputedConceptsLow-dose computed tomographyLung cancer mortalityLung cancerLDCT screeningCancer deathCancer mortalityEffect of LDCTSystematic reviewNational Lung Screening TrialEvidence-based clinical guidelinesFrequency of followLung cancer deathsLung cancer screeningRisk of deathPotential harmAdvanced diseaseCause mortalityCohort studyMost patientsSecondary outcomesMajor complicationsPrimary outcomeRandomized studyRandomized trialsCT screeningCounterpoint: Are Limited Resections Appropriate in Non-small Cell Lung Cancer? No Don't Overdo It, and Don't Get Confused
Detterbeck FC. Counterpoint: Are Limited Resections Appropriate in Non-small Cell Lung Cancer? No Don't Overdo It, and Don't Get Confused. CHEST Journal 2012, 141: 590-592. PMID: 22396559, DOI: 10.1378/chest.11-3110.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsCarcinoma, Non-Small-Cell LungHumansLungLung NeoplasmsPneumonectomyRandomized Controlled Trials as TopicSurvival RateTomography, X-Ray Computed
2008
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)
Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA, Govindan R, Peng G, Monberg MJ, Obasaju CK, Socinski MA. Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Supportive Care In Cancer 2008, 17: 307-313. PMID: 18781341, DOI: 10.1007/s00520-008-0489-y.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingProspective StudiesPsychiatric Status Rating ScalesQuality of LifeRandomized Controlled Trials as TopicConceptsLung Cancer Symptom ScaleNon-small cell lung cancerQuality of lifeCancer Symptom ScaleCell lung cancerNeoadjuvant therapyPostsurgical evaluationLung cancerSymptom ScaleEarly-stage non-small cell lung cancerStage non-small cell lung cancerClinical stage IECOG performance statusSubgroup of patientsModalities of treatmentSignificant survival gainStable QOLConclusionsMost patientsNeoadjuvant trialsAdjuvant approachPerformance statusPreoperative chemotherapyComplete resectionStable symptomsSurvival gain
2004
Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer
Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. Journal Of Clinical Oncology 2004, 22: 4837-4845. PMID: 15570087, DOI: 10.1200/jco.2004.01.178.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyConfidence IntervalsDose Fractionation, RadiationDose-Response Relationship, RadiationHumansLung NeoplasmsNeoplasm StagingOdds RatioPneumonectomyPrognosisRadiotherapy DosageRadiotherapy, AdjuvantRandomized Controlled Trials as TopicRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsThoracic radiation therapyPlatinum-based chemotherapyRisk ratioRadiation therapyLS-SCLCLung cancerLimited-stage small cell lung cancerSmall cell lung cancerHyperfractionated radiation therapyLimited-Stage SmallProphylactic cranial irradiationCombined modality therapyCell lung cancerCranial irradiationChemotherapy regimensChemotherapeutic regimenModality therapySurvival benefitRandomized trialsDaily fractionationSubset analysisRadiation fractionationRT relativeRisk differenceChemotherapy